FDA TEMPO Pilot Lets AI Devices Reach Patients Pre-Authorization — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- FDA launched its TEMPO pilot program, provisionally allowing select generative AI medical device developers to release products on the market without prior marketing authorization.
- Cadence and Limbic are among four devices recently accepted into the TEMPO pilot, according to STAT+.
- The TEMPO pilot is designed to expand the pool of technologies eligible for the Medicare ACCESS model, an experiment in paying for technology that helps beneficiaries manage chronic conditions.
- Medicare ACCESS model is a payment experiment tying reimbursement to digital tools that help beneficiaries manage chronic conditions, and TEMPO serves as a supply pipeline for it.
- The pilot doubles as a live regulatory sandbox, giving the FDA and participating companies a chance to experiment with how generative AI devices should be overseen in real-world use.
Why it matters: Four AI device makers — including Cadence and Limbic — are now selling to patients without FDA marketing authorization, making Medicare's chronic-care payment model the first real-world test bed for how generative AI medical tools get regulated. The FDA is effectively outsourcing parts of its rulemaking to market deployment, meaning whatever happens with these four products will shape future authorization standards.
Ask SkimNews
